I was very disappointed to learn that yet another pain therapy under study has been "suspended" by the company... in this case Johnson & Johnson has halted the fulranumab study that we promoted just last week.... just as Pfizer suspended the tanezumab study last summer. Two blows for the IC community. AstraZeneca and Regeneron have halted similar studies as well.
Why?? While these medications were believed to be the next generation in pain medication targeting nerve growth, clinical trials studying their effectiveness in reducing back pain revealed that they apparently disrupted the blood supply to bone leading to bone death, joint deterioration, osteoarthritis and, for some patients, the need for joint replacement surgery.
I find myself very disappointed by the news. I had great hopes for this new type of pain medication.
Jill
Why?? While these medications were believed to be the next generation in pain medication targeting nerve growth, clinical trials studying their effectiveness in reducing back pain revealed that they apparently disrupted the blood supply to bone leading to bone death, joint deterioration, osteoarthritis and, for some patients, the need for joint replacement surgery.
I find myself very disappointed by the news. I had great hopes for this new type of pain medication.
Jill
Comment